We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
DYNLL1 is not prognostic in Glioblastoma Multiforme (TCGA)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
694.9
Number of samples
141
Samples
Sample
Description
TPM
TCGA-28-5220-01A
0 years, male, white, stage:'--, dead, 388 days
1247.0
TCGA-06-5411-01A
0 years, male, white, stage:'--, dead, 254 days
1203.9
TCGA-12-5295-01A
0 years, female, white, stage:'--, dead, 454 days
1152.5
TCGA-06-0238-01A
0 years, male, white, stage:'--, dead, 405 days
1145.0
TCGA-14-1829-01A
0 years, male, black or african american, stage:'--, alive, 218 days
1141.6
TCGA-06-0219-01A
0 years, male, white, stage:'--, dead, 22 days
1083.8
TCGA-32-5222-01A
0 years, male, white, stage:'--, dead, 585 days
1060.1
TCGA-28-5216-01A
0 years, male, white, stage:'--, alive, 415 days
1052.2
TCGA-12-0821-01A
0 years, male, white, stage:'--, dead, 323 days
1048.6
TCGA-14-1825-01A
0 years, male, white, stage:'--, dead, 232 days
1047.0
TCGA-32-1980-01A
0 years, male, white, stage:'--, dead, 36 days
1038.3
TCGA-06-0686-01A
0 years, male, white, stage:'--, dead, 432 days
1034.9
TCGA-06-5416-01A
0 years, female, white, stage:'--, alive, 204 days
1034.7
TCGA-27-2526-01A
0 years, female, white, stage:'--, dead, 87 days
994.1
TCGA-14-2554-01A
0 years, female, white, stage:'--, dead, 532 days
968.0
TCGA-06-0749-01A
0 years, male, black or african american, stage:'--, dead, 82 days
967.9
TCGA-06-2558-01A
0 years, female, white, stage:'--, dead, 380 days
953.4
TCGA-28-5215-01A
0 years, female, white, stage:'--, dead, 335 days
946.2
TCGA-06-0132-01A
0 years, male, white, stage:'--, dead, 771 days
940.1
TCGA-12-0616-01A
0 years, female, white, stage:'--, dead, 448 days
913.1
TCGA-06-0644-01A
0 years, male, black or african american, stage:'--, dead, 384 days
907.9
TCGA-27-2523-01A
0 years, male, white, stage:'--, dead, 489 days
881.3
TCGA-14-1823-01A
0 years, female, white, stage:'--, dead, 543 days
873.6
TCGA-06-0745-01A
0 years, male, white, stage:'--, dead, 239 days
873.1
TCGA-06-5413-01A
0 years, male, white, stage:'--, alive, 268 days
868.0
TCGA-27-2524-01A
0 years, male, white, stage:'--, dead, 231 days
860.8
TCGA-76-4929-01A
0 years, female, white, stage:'--, dead, 111 days
858.1
TCGA-02-2486-01A
0 years, male, white, stage:'--, dead, 618 days
833.0
TCGA-06-0138-01A
0 years, male, white, stage:'--, dead, 737 days
832.5
TCGA-06-0130-01A
0 years, male, white, stage:'--, dead, 394 days
826.3
TCGA-12-3652-01A
0 years, male, white, stage:'--, dead, 1062 days
823.6
TCGA-12-5299-01A
0 years, female, white, stage:'--, dead, 98 days
822.8
TCGA-12-3653-01A
0 years, female, white, stage:'--, dead, 442 days
813.2
TCGA-26-5135-01A
0 years, female, white, stage:'--, dead, 270 days
788.4
TCGA-76-4932-01A
0 years, female, white, stage:'--, dead, 1458 days
782.0
TCGA-27-2519-01A
0 years, male, white, stage:'--, dead, 550 days
779.5
TCGA-19-4065-01A
0 years, male, white, stage:'--, alive, 214 days
777.0
TCGA-27-1831-01A
0 years, male, white, stage:'--, dead, 505 days
775.9
TCGA-15-1444-01A
0 years, male, white, stage:'--, dead, 1537 days
775.9
TCGA-06-0156-01A
0 years, male, white, stage:'--, dead, 178 days
775.1
TCGA-27-2528-01A
0 years, male, white, stage:'--, dead, 480 days
766.2
TCGA-32-2616-01A
0 years, female, white, stage:'--, dead, 224 days
765.5
TCGA-28-5208-01A
0 years, male, white, stage:'--, dead, 544 days
764.4
TCGA-76-4927-01A
0 years, male, white, stage:'--, dead, 535 days
762.0
TCGA-06-2563-01A
0 years, female, white, stage:'--, alive, 932 days
748.5
TCGA-06-5412-01A
0 years, female, white, stage:'--, dead, 138 days
744.6
TCGA-12-3650-01A
0 years, male, white, stage:'--, dead, 333 days
743.6
TCGA-41-5651-01A
0 years, female, black or african american, stage:'--, dead, 460 days
738.3
TCGA-06-5858-01A
0 years, female, white, stage:'--, alive, 187 days
735.8
TCGA-14-0817-01A
0 years, female, white, stage:'--, dead, 164 days
727.0
TCGA-28-5207-01A
0 years, male, white, stage:'--, dead, 343 days
726.3
TCGA-06-5859-01A
0 years, male, white, stage:'--, alive, 139 days
723.7
TCGA-41-2572-01A
0 years, male, white, stage:'--, dead, 406 days
716.7
TCGA-28-2509-01A
0 years, female, white, stage:'--, alive, 145 days
707.6
TCGA-15-0742-01A
0 years, male, white, stage:'--, dead, 419 days
706.2
TCGA-14-0787-01A
0 years, male, asian, stage:'--, dead, 68 days
702.1
TCGA-06-2561-01A
0 years, female, white, stage:'--, dead, 537 days
701.8
TCGA-06-5418-01A
0 years, female, white, stage:'--, dead, 83 days
696.5
TCGA-26-5139-01A
0 years, female, white, stage:'--, alive, 48 days
695.2
TCGA-76-4931-01A
0 years, female, white, stage:'--, dead, 279 days
694.3
TCGA-06-0743-01A
0 years, male, white, stage:'--, dead, 803 days
693.7
TCGA-32-2634-01A
0 years, male, white, stage:'--, alive, 693 days
691.9
TCGA-41-2571-01A
0 years, male, white, stage:'--, dead, 26 days
688.1
TCGA-19-1390-01A
0 years, female, white, stage:'--, dead, 772 days
683.8
TCGA-27-1837-01A
0 years, male, white, stage:'--, dead, 427 days
683.3
TCGA-06-0750-01A
0 years, male, white, stage:'--, dead, 28 days
677.4
TCGA-06-0882-01A
0 years, male, white, stage:'--, dead, 632 days
675.7
TCGA-28-5204-01A
0 years, male, white, stage:'--, dead, 454 days
674.0
TCGA-06-5408-01A
0 years, female, white, stage:'--, dead, 357 days
666.0
TCGA-32-2615-01A
0 years, male, white, stage:'--, dead, 485 days
665.7
TCGA-16-0846-01A
0 years, male, white, stage:'--, dead, 119 days
663.5
TCGA-06-2564-01A
0 years, male, white, stage:'--, alive, 181 days
649.9
TCGA-27-1834-01A
0 years, male, white, stage:'--, dead, 1233 days
649.2
TCGA-19-2624-01A
0 years, male, white, stage:'--, dead, 5 days
639.9
TCGA-06-5410-01A
0 years, female, white, stage:'--, dead, 108 days
638.3
TCGA-26-5132-01A
0 years, male, white, stage:'--, alive, 286 days
628.4
TCGA-06-2570-01A
0 years, female, white, stage:'--, alive, 958 days
624.9
TCGA-06-0141-01A
0 years, male, white, stage:'--, dead, 313 days
624.7
TCGA-06-0168-01A
0 years, female, white, stage:'--, dead, 598 days
624.7
TCGA-06-0187-01A
0 years, male, white, stage:'--, dead, 828 days
623.0
TCGA-27-2521-01A
0 years, male, white, stage:'--, dead, 510 days
622.8
TCGA-06-0210-01A
0 years, female, white, stage:'--, dead, 225 days
622.6
TCGA-06-0139-01A
0 years, male, white, stage:'--, dead, 362 days
613.0
TCGA-06-0174-01A
0 years, male, white, stage:'--, dead, 98 days
609.1
TCGA-06-2559-01A
0 years, male, white, stage:'--, dead, 150 days
608.7
TCGA-02-2485-01A
0 years, male, black or african american, stage:'--, alive, 470 days
604.2
TCGA-06-2557-01A
0 years, male, black or african american, stage:'--, dead, 33 days
604.1
TCGA-28-5209-01A
0 years, female, white, stage:'--, alive, 442 days
604.0
TCGA-06-5414-01A
0 years, male, white, stage:'--, alive, 273 days
603.1
TCGA-27-1832-01A
0 years, female, white, stage:'--, dead, 300 days
600.9
TCGA-28-5218-01A
0 years, male, white, stage:'--, dead, 157 days
600.8
TCGA-06-0125-01A
0 years, female, white, stage:'--, dead, 1448 days
598.9
TCGA-06-0645-01A
0 years, female, white, stage:'--, dead, 175 days
598.1
TCGA-06-0190-01A
0 years, male, white, stage:'--, dead, 317 days
597.0
TCGA-06-0184-01A
0 years, male, white, stage:'--, dead, 2126 days
595.5
TCGA-19-2625-01A
0 years, female, white, stage:'--, dead, 124 days
595.3
TCGA-06-0211-01A
0 years, male, white, stage:'--, dead, 360 days
595.2
TCGA-06-5856-01A
0 years, male, white, stage:'--, dead, 114 days
593.4
TCGA-06-2562-01A
0 years, male, white, stage:'--, dead, 382 days
591.6
TCGA-28-2514-01A
0 years, male, asian, stage:'--, alive, 160 days
588.3
TCGA-27-1830-01A
0 years, male, white, stage:'--, dead, 154 days
587.9
TCGA-06-2567-01A
0 years, male, white, stage:'--, dead, 133 days
576.2
TCGA-02-0047-01A
0 years, male, white, stage:'--, dead, 448 days
574.2
TCGA-32-1982-01A
0 years, female, white, stage:'--, dead, 142 days
572.2
TCGA-28-1753-01A
0 years, male, white, stage:'--, alive, 37 days
571.7
TCGA-32-2632-01A
0 years, male, white, stage:'--, dead, 269 days
570.6
TCGA-32-1970-01A
0 years, male, white, stage:'--, dead, 468 days
564.2
TCGA-06-0178-01A
0 years, male, white, stage:'--, dead, 2681 days
563.8
TCGA-08-0386-01A
0 years, male, white, stage:'--, dead, 548 days
562.6
TCGA-26-5133-01A
0 years, male, white, stage:'--, alive, 452 days
558.1
TCGA-14-1034-01A
0 years, female, stage:'--, dead, 485 days
557.1
TCGA-14-0871-01A
0 years, female, white, stage:'--, dead, 880 days
556.5
TCGA-41-3915-01A
0 years, male, white, stage:'--, dead, 360 days
551.6
TCGA-12-0618-01A
0 years, male, white, stage:'--, dead, 395 days
545.1
TCGA-02-2483-01A
0 years, male, asian, stage:'--, alive, 466 days
542.9
TCGA-32-2638-01A
0 years, male, white, stage:'--, dead, 766 days
537.3
TCGA-06-0158-01A
0 years, male, white, stage:'--, dead, 329 days
536.7
TCGA-06-2569-01A
0 years, female, black or african american, stage:'--, alive, 13 days
531.1
TCGA-06-0646-01A
0 years, male, white, stage:'--, dead, 175 days
530.3
TCGA-41-4097-01A
0 years, female, white, stage:'--, dead, 6 days
529.0
TCGA-19-2629-01A
0 years, male, white, stage:'--, dead, 737 days
518.7
TCGA-02-0055-01A
0 years, female, white, stage:'--, dead, 76 days
513.0
TCGA-06-0747-01A
0 years, male, white, stage:'--, dead, 82 days
511.1
TCGA-06-0157-01A
0 years, female, white, stage:'--, dead, 97 days
506.5
TCGA-27-1835-01A
0 years, female, white, stage:'--, dead, 648 days
505.1
TCGA-26-1442-01A
0 years, male, white, stage:'--, alive, 953 days
503.0
TCGA-28-2513-01A
0 years, female, white, stage:'--, alive, 222 days
502.6
TCGA-06-2565-01A
0 years, male, asian, stage:'--, dead, 506 days
501.5
TCGA-76-4925-01A
0 years, male, white, stage:'--, dead, 146 days
501.4
TCGA-06-5417-01A
0 years, female, white, stage:'--, alive, 155 days
500.0
TCGA-06-0878-01A
0 years, male, white, stage:'--, alive, 218 days
493.7
TCGA-06-1804-01A
0 years, female, white, stage:'--, dead, 414 days
490.4
TCGA-06-0744-01A
0 years, male, white, stage:'--, dead, 1426 days
469.6
TCGA-19-2620-01A
0 years, male, white, stage:'--, dead, 148 days
444.3
TCGA-14-0789-01A
0 years, male, white, stage:'--, dead, 342 days
428.6
TCGA-32-4213-01A
0 years, female, white, stage:'--, alive, 604 days
395.4
TCGA-19-5960-01A
0 years, male, white, stage:'--, dead, 455 days
393.3
TCGA-12-0619-01A
0 years, male, white, stage:'--, dead, 1062 days
361.7
TCGA-26-5134-01A
0 years, male, white, stage:'--, alive, 167 days
353.3
TCGA-19-2619-01A
0 years, female, black or african american, stage:'--, alive, 294 days
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
DYNLL1 is not prognostic in Glioblastoma Multiforme (validation)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
3-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
3-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
46.2
Number of samples
58
Samples
Sample
Description
TPM
AK156
N, NA, stage:NA, dead, 330 days
84.2
AK142
N, NA, stage:NA, alive, 90 days
65.5
AK236
N, NA, stage:NA, dead, 360 days
64.5
AK173
N, NA, stage:NA, dead, 180 days
61.2
AK015
N, NA, stage:NA, alive, 720 days
61.0
AK231
N, NA, stage:NA, dead, 240 days
59.5
AK195
N, NA, stage:NA, dead, 390 days
56.9
AK079
N, NA, stage:NA, dead, 210 days
55.8
AK153
N, NA, stage:NA, dead, 240 days
55.8
AK051
N, NA, stage:NA, dead, 360 days
55.4
AK134
N, NA, stage:NA, dead, 360 days
54.4
AK199
N, NA, stage:NA, alive, 1860 days
54.1
AK133
N, NA, stage:NA, dead, 360 days
54.0
AK158
N, NA, stage:NA, dead, 360 days
53.9
AK216
N, NA, stage:NA, dead, 360 days
53.2
AK124
N, NA, stage:NA, alive, 1920 days
53.0
AK074
N, NA, stage:NA, alive, 300 days
52.8
AK165
N, NA, stage:NA, alive, 360 days
52.2
AK049
N, NA, stage:NA, dead, 180 days
50.9
AK149
N, NA, stage:NA, dead, 420 days
50.8
AK183
N, NA, stage:NA, alive, 360 days
50.7
AK030
N, NA, stage:NA, dead, 120 days
50.5
AK227
N, NA, stage:NA, alive, 300 days
50.3
AK123
N, NA, stage:NA, dead, 180 days
49.9
AK002
N, NA, stage:NA, dead, 570 days
49.7
AK072
N, NA, stage:NA, dead, 150 days
47.0
AK167
N, NA, stage:NA, dead, 180 days
46.3
AK071
N, NA, stage:NA, dead, 540 days
46.2
AK117
N, NA, stage:NA, dead, 210 days
45.6
AK068
N, NA, stage:NA, alive, 360 days
45.2
AK188
N, NA, stage:NA, alive, 420 days
45.0
AK185
N, NA, stage:NA, alive, 330 days
44.9
AK213
N, NA, stage:NA, alive, 2010 days
44.6
AK089
N, NA, stage:NA, dead, 330 days
44.6
AK139
N, NA, stage:NA, dead, 270 days
43.2
AK218
N, NA, stage:NA, dead, 180 days
43.0
AK098
N, NA, stage:NA, dead, 660 days
42.9
AK081
N, NA, stage:NA, dead, 180 days
42.8
AK088
N, NA, stage:NA, dead, 360 days
41.2
AK003
N, NA, stage:NA, dead, 600 days
41.1
AK053
N, NA, stage:NA, dead, 300 days
40.9
AK178
N, NA, stage:NA, dead, 240 days
40.2
AK226
N, NA, stage:NA, dead, 360 days
40.1
AK055
N, NA, stage:NA, dead, 240 days
39.9
AK099
N, NA, stage:NA, dead, 420 days
39.3
AK066
N, NA, stage:NA, alive, 960 days
39.2
AK006
N, NA, stage:NA, dead, 360 days
38.7
AK076
N, NA, stage:NA, alive, 660 days
38.5
AK035
N, NA, stage:NA, dead, 210 days
38.0
AK043
N, NA, stage:NA, alive, 660 days
36.8
AK100
N, NA, stage:NA, alive, 960 days
34.8
AK091
N, NA, stage:NA, dead, 210 days
34.7
AK103
N, NA, stage:NA, alive, 1320 days
32.4
AK005
N, NA, stage:NA, dead, 240 days
29.7
AK085
N, NA, stage:NA, alive, 660 days
27.0
AK041
N, NA, stage:NA, alive, 810 days
26.2
AK205
N, NA, stage:NA, dead, 120 days
22.1
AK102
N, NA, stage:NA, alive, 1740 days
21.5
Show allShow less
GLIOBLASTOMA MULTIFORME - Protein relative expression (CPTAC)
Number of samples
110
Samples
Sample ID
Sample type
nRPX
CPT0204390003
Normal
1.3
CPT0204380003
Normal
1.3
CPT0204400003
Normal
1.1
CPT0204410003
Normal
1.1
CPT0204330003
Normal
1.1
CPT0204360003
Normal
1.1
CPT0204420003
Normal
1.1
CPT0204370003
Normal
1.1
CPT0204340003
Normal
1.0
CPT0204350003
Normal
0.9
CPT0217100003
Tumor
0.4
CPT0190240004
Tumor
0.3
CPT0217880003
Tumor
0.3
CPT0104220003
Tumor
0.3
CPT0209440003
Tumor
0.3
CPT0206450003
Tumor
0.3
CPT0167860004
Tumor
0.3
CPT0206330003
Tumor
0.3
CPT0207030003
Tumor
0.2
CPT0225760003
Tumor
0.2
CPT0205890003
Tumor
0.2
CPT0196850003
Tumor
0.2
CPT0168720003
Tumor
0.2
CPT0205570003
Tumor
0.2
CPT0182580003
Tumor
0.1
CPT0189460003
Tumor
0.1
CPT0182550003
Tumor
0.1
CPT0205670004
Tumor
0.1
CPT0189250003
Tumor
0.1
CPT0199770003
Tumor
0.1
CPT0104330003
Tumor
0.1
CPT0168270003
Tumor
0.1
CPT0201710003
Tumor
0.1
CPT0228220003
Tumor
0.1
CPT0175060003
Tumor
0.1
CPT0161730003
Tumor
0.1
CPT0217710008
Tumor
0.1
CPT0093450003
Tumor
0.1
CPT0190360004
Tumor
0.1
CPT0218770003
Tumor
0.1
CPT0206880003
Tumor
0.1
CPT0207090003
Tumor
0.1
CPT0218960004
Tumor
0.0
CPT0218890004
Tumor
0.0
CPT0087680003
Tumor
0.0
CPT0189570004
Tumor
0.0
CPT0078580003
Tumor
0.0
CPT0206670004
Tumor
0.0
CPT0167750004
Tumor
0.0
CPT0221180003
Tumor
0.0
CPT0125220003
Tumor
-0.1
CPT0162140003
Tumor
-0.1
CPT0218330004
Tumor
-0.1
CPT0123530003
Tumor
-0.1
CPT0189850004
Tumor
-0.1
CPT0162020003
Tumor
-0.1
CPT0093510003
Tumor
-0.1
CPT0218690004
Tumor
-0.1
CPT0167970003
Tumor
-0.1
CPT0224330003
Tumor
-0.1
CPT0218670003
Tumor
-0.1
CPT0208980003
Tumor
-0.1
CPT0168590003
Tumor
-0.2
CPT0168830003
Tumor
-0.2
CPT0064650003
Tumor
-0.2
CPT0168380003
Tumor
-0.2
CPT0127420003
Tumor
-0.2
CPT0225730003
Tumor
-0.2
CPT0168480003
Tumor
-0.2
CPT0087730003
Tumor
-0.2
CPT0087950003
Tumor
-0.2
CPT0205450004
Tumor
-0.2
CPT0189750004
Tumor
-0.2
CPT0167640003
Tumor
-0.2
CPT0168080003
Tumor
-0.2
CPT0002410011
Tumor
-0.2
CPT0206000004
Tumor
-0.2
CPT0125510003
Tumor
-0.2
CPT0206780003
Tumor
-0.3
CPT0071100003
Tumor
-0.3
CPT0205780003
Tumor
-0.3
CPT0224390004
Tumor
-0.3
CPT0127480003
Tumor
-0.3
CPT0171580008
Tumor
-0.3
CPT0092440003
Tumor
-0.3
CPT0167530003
Tumor
-0.3
CPT0206560003
Tumor
-0.3
CPT0162100003
Tumor
-0.3
CPT0089150003
Tumor
-0.3
CPT0206230003
Tumor
-0.3
CPT0093360003
Tumor
-0.3
CPT0186100003
Tumor
-0.3
CPT0219080004
Tumor
-0.3
CPT0093590003
Tumor
-0.3
CPT0093550003
Tumor
-0.3
CPT0217060003
Tumor
-0.3
CPT0217190003
Tumor
-0.3
CPT0224600003
Tumor
-0.3
CPT0224540004
Tumor
-0.4
CPT0217000004
Tumor
-0.4
CPT0206110003
Tumor
-0.4
CPT0182500003
Tumor
-0.4
CPT0064890003
Tumor
-0.4
CPT0087570003
Tumor
-0.4
CPT0217430008
Tumor
-0.5
CPT0125570003
Tumor
-0.5
CPT0189650004
Tumor
-0.5
CPT0079790003
Tumor
-0.5
CPT0218830004
Tumor
-0.5
CPT0216920008
Tumor
-0.6
Show allShow less
GLIOMA - Protein expressioni
A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.
Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.